Eli Lilly’s $7 billion deal for Kelonia Therapeutics on Monday was simply the most recent instance of the sky-high costs that Big Pharmas are prepared to pay for in vivo CAR-T tech. In truth, it was the corporate’s second play for the area this 12 months—having bought Orna Therapeutics for up to $2.4 billion in February.
Lilly joined the likes of Gilead Sciences, which acquired in vivo CAR-T firm Interius BioTherapeutics for $350 million in August 2025 and struck a deal with Pregene Biopharma price up to $1.6 billion by way of Kite two months later. Last 12 months additionally noticed AbbVie buy Capstan Therapeutics for $2.1 billion, Bristol Myers Squibb acquire Orbital Therapeutics for $1.5 billion, and AstraZeneca pick up EsoBiotec for $1 billion.
But regardless of this current “feeding frenzy,” Pitchbook’s Ben Zercher informed Fierce he expects in vivo CAR-T dealmaking to sluggish—not from lack of curiosity, however from a scarcity of viable acquisition targets.
He pointed to Johnson & Johnson and Novartis as notable Big Pharmas that also don’t personal any in vivo CAR-T applications. In phrases of biotechs nonetheless up for grabs, Zercher recognized Umoja Biopharma as an apparent remaining goal for hungry patrons.
Seattle-based Umoja has two candidates already in the clinic. One of those, the CD22-targeting autoimmune and non-Hodgkin lymphoma candidate UB-VV400/410, is in part 1 research in China. The different clinical-stage candidate is UB-VV111, a CD19-targeting in vivo CAR-T hematology asset additionally in a part 1 examine.
UB-VV111 has already caught the attention of AbbVie, which penned a $1.4 billion biobucks deal again in 2024 for the choice to license the asset at a later date. That similar deal additionally gave AbbVie the choice to increase the pact to cowl 4 further in-situ candidates, aimed toward targets chosen by the Big Pharma.
Despite the attractiveness of Umoja’s in vivo gene supply tech to potential patrons, the present partnership with AbbVie may complicate a clear acquisition by one other Big Pharma, Zercher recommended.
“Fewer buyers and fewer sellers will slow the pace of deals,” he stated. “Buyers may also look offshore, where Chinese players like Starna Therapeutics are advancing in vivo CAR-T into the clinic.”
Suzhou-based Starna secured a 300 million RMB ($44 million) sequence B final October that was backed by the likes of Lilly Asia Ventures. The RNA biotech stated on the time that a part of the funds could be used to advance its in vivo CAR-T pipeline, which is led by an autoimmune-focused candidate that is already in the clinic. Starna can be creating a clinical-stage vaccine for respiratory syncytial virus and a therapeutic vaccine for strong tumors.
Worth the cash?
The restricted pool of potential belongings additionally means firms will want to maximize what they’ve. Zercher argued that the potential of in vivo CAR-T justifies excessive upfront costs—even for early-stage belongings. That’s very true due to the chance to increase past oncology into autoimmune indications, he identified.
“The dual-market potential justifies what would normally be seen as an overpay for early-stage assets,” he stated.
Traditional autologous CAR-T remedy requires engineering a affected person’s personal T cells to battle most cancers earlier than reinfusing them into the physique. In distinction, in vivo CAR-T makes use of gene enhancing to generate CAR-T cells inside a affected person’s physique.
So far, in vivo CAR-Ts have proven early promise as a extra environment friendly and doubtlessly equally efficient various, in accordance to Leerink Partners analyst Daina Graybosch, Ph.D.
When it comes to Big Pharmas digging deep into their pockets to pay for these firms, she recommended there are two predominant motives.
“I think most of the deal flow is defensive,” Graybosch informed Fierce in an interview. “Companies have invested heavily in [CAR-T] platforms with high barriers to entry. If disruption is coming, they need to be the disruptors.”
Gilead’s technique may doubtlessly be seen in this gentle. The drugmaker has tasted success with its accepted autologous CAR-T therapies Yescarta and Tecartus, developed by its Kite Pharma unit. But this might be put in danger if in vivo approaches show disruptive.
At the identical time, Gilead has witnessed recent sales declines for its accepted CAR-T medication due to intense competitors. Amid these exterior pressures, the pharma could also be in search of a solution with next-gen tech.
Meanwhile, the principle aim for newer entrants like Lilly could also be to construct a diversified portfolio of modalities, which helps navigate uncertainty.
“With cell therapy, we think we’re smarter than we are,” Graybosch stated. “It’s helpful to have diversity in what you buy.”
Still, scientific knowledge will in the end determine the sector’s destiny. Graybosch famous the low toxicity noticed in Kelonia’s early knowledge, however is watching intently to see whether or not these outcomes maintain in bigger affected person populations, notably in U.S. trials.
She can be targeted on whether or not remedies could be delivered in outpatient settings fairly than in intensive care, a key limitation of the remedies to date.
Graybosch stated she is already maintaining a tally of Umoja’s UB-VV111—which received FDA quick observe designation final September—in addition to Legend Biotech, which lately treated its first affected person with an in vivo candidate and expects knowledge later this 12 months.
But in a quickly evolving CAR-T panorama, Graybosch cautioned in opposition to overinterpreting early outcomes.
“There’s a lot of overreactions to small data sets,” she informed Fierce. “The first sufferers being placed on any of those therapies are the worst sufferers to take a look at, as a result of there’s one thing particular about these folks. They’re being watched in other ways. They have uncommon entry and the medical doctors are overselected.
“Forget all those,” she continued. “I’m more interested in 40- to 50-patient data sets with real follow-up to start to understand the potential and the challenges.”
Why Kelonia virtually didn’t make it
While Kelonia’s story seems to be set to finish with a hefty buyout by Lilly, the biotech actually confronted its personal challenges alongside the best way, in accordance to Kelonia board member Bryan Roberts.
Despite promising science and scientific progress, there was some extent when the lentiviral vector supply specialist “failed spectacularly” to elevate the capital wanted to proceed, in accordance to Roberts, who can be a accomplice at Kelonia investor Venrock.
The hassle started in 2022, when the biotech market cooled after the bullish post-COVID-19 surge. That shift strained enterprise group Venrock’s means to proceed supporting the corporate after seeding Kelonia in late 2020.
For the subsequent couple of years, Kelonia had to do extra with much less. “We got up to the brink of not having any money a couple times,” Roberts informed Fierce in an interview.
An $800 million biobucks licensing deal with Astellas Pharma in early 2024 gave the biotech some respiratory room, however Roberts stated Venrock nonetheless had to present a bridge mortgage to preserve operations shifting.
After an early trial of its BCMA-targeting in vivo CAR-T, dubbed KLN-1010, started in Australia, Kelonia once more neared a money crunch earlier than securing a partnership with Johnson & Johnson in November 2025. The turning level, Roberts stated, got here with first-in-human data offered on the American Society of Hematology convention later that month, together with a late-breaking oral presentation on the corporate’s lead asset, a BCMA-targeting in vivo CAR-T referred to as KLN-1010.
Although the dataset included simply three sufferers, the corporate reported that refractory a number of myeloma sufferers in the part 1 trial achieved minimal residual illness negativity at one month, which persevered by way of three months.
“That was what created a consensus view that Kelonia had something really interesting,” Roberts stated. “The strength of the clinical data turned people around.”
Now, just some months later, Kelonia and its lead asset are in line to turn into the property of Eli Lilly. The buyout options $3.25 billion upfront, with the potential to attain $7 billion altogether, together with milestones. Roberts stated Venrock’s funding may return greater than 45 instances its authentic stake.
“It’s possible to build these businesses more capital-efficiently,” Roberts stated. “And clinical data trumps everything.”
Though Kelonia’s journey was a funding curler coaster, the ex vivo CAR-T market has remained on a gradual upward trajectory. Roberts stated the surge in curiosity could be defined by the truth that in vivo approaches purpose to match the efficacy of their ex vivo predecessors whereas avoiding their important drawbacks, together with unwanted effects, manufacturing delays and excessive prices.
“The goal is to match its efficacy and improve everything else,” Roberts stated.
“We need more patients and more time, but I believe that’s achievable,” he added. “Ex vivo CAR-T will soon go the way of the buffalo.”
